JP7311267B2 - 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 - Google Patents

急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 Download PDF

Info

Publication number
JP7311267B2
JP7311267B2 JP2018555315A JP2018555315A JP7311267B2 JP 7311267 B2 JP7311267 B2 JP 7311267B2 JP 2018555315 A JP2018555315 A JP 2018555315A JP 2018555315 A JP2018555315 A JP 2018555315A JP 7311267 B2 JP7311267 B2 JP 7311267B2
Authority
JP
Japan
Prior art keywords
active agent
individual
administration
nac
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018555315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501226A (ja
JP2019501226A5 (enExample
Inventor
ネストレム，ジャック
ヤコブソン，スヴェン
ヘンリクセン，デニス
アルスチン，ジェームス ファン
Original Assignee
エゲティス・セラピューティクス・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エゲティス・セラピューティクス・アーベー filed Critical エゲティス・セラピューティクス・アーベー
Publication of JP2019501226A publication Critical patent/JP2019501226A/ja
Publication of JP2019501226A5 publication Critical patent/JP2019501226A5/ja
Priority to JP2021197319A priority Critical patent/JP7374163B2/ja
Application granted granted Critical
Publication of JP7311267B2 publication Critical patent/JP7311267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018555315A 2016-01-11 2017-01-10 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 Active JP7311267B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021197319A JP7374163B2 (ja) 2016-01-11 2021-12-03 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277232P 2016-01-11 2016-01-11
US62/277,232 2016-01-11
US201662361605P 2016-07-13 2016-07-13
US62/361,605 2016-07-13
PCT/IB2017/050115 WO2017122120A1 (en) 2016-01-11 2017-01-10 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021197319A Division JP7374163B2 (ja) 2016-01-11 2021-12-03 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤

Publications (3)

Publication Number Publication Date
JP2019501226A JP2019501226A (ja) 2019-01-17
JP2019501226A5 JP2019501226A5 (enExample) 2020-02-20
JP7311267B2 true JP7311267B2 (ja) 2023-07-19

Family

ID=57909814

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555315A Active JP7311267B2 (ja) 2016-01-11 2017-01-10 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
JP2021197319A Active JP7374163B2 (ja) 2016-01-11 2021-12-03 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021197319A Active JP7374163B2 (ja) 2016-01-11 2021-12-03 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤

Country Status (8)

Country Link
US (2) US11260060B2 (enExample)
EP (2) EP3842040B1 (enExample)
JP (2) JP7311267B2 (enExample)
CN (1) CN108601757A (enExample)
AU (1) AU2017208123B2 (enExample)
CA (1) CA3010915C (enExample)
RU (1) RU2018128793A (enExample)
WO (1) WO2017122120A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842040B1 (en) * 2016-01-11 2022-03-09 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
RU2693677C1 (ru) * 2018-10-15 2019-07-03 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ гемокоррекции при лечении печеночной недостаточности
CN113993529A (zh) * 2019-05-21 2022-01-28 潘德勒姆治疗公司 用于治疗肝脏病症的方法和组合物
WO2022269026A1 (en) 2021-06-25 2022-12-29 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Treating acetaminophen overdose
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070607A1 (en) 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP2005508840A (ja) 2001-03-30 2005-04-07 バイオアドヴァンテックス ファーマ インコーポレイテッド Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2010507572A (ja) 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
JP2010513229A (ja) 2006-12-09 2010-04-30 エム． ソダーリング、エリック 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物
JP2012532189A (ja) 2009-07-06 2012-12-13 プレッドファルマ・アーベー マンガン錯体化合物と非マンガン錯体形態の同化合物の組み合わせを用いる医薬組成物及び治療方法
JP2015504066A (ja) 2012-01-05 2015-02-05 プレッドファルマ・アーベー カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
US20140178358A1 (en) * 2012-12-21 2014-06-26 The United States of America as represented by the Secretary of Department of Health and Human Servi Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker
EP3842040B1 (en) 2016-01-11 2022-03-09 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508840A (ja) 2001-03-30 2005-04-07 バイオアドヴァンテックス ファーマ インコーポレイテッド Ｎ−アセチルシステイン組成物及び薬剤毒性治療または防止方法
US20050070607A1 (en) 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
JP2010507572A (ja) 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
JP2010513229A (ja) 2006-12-09 2010-04-30 エム． ソダーリング、エリック 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物
JP2012532189A (ja) 2009-07-06 2012-12-13 プレッドファルマ・アーベー マンガン錯体化合物と非マンガン錯体形態の同化合物の組み合わせを用いる医薬組成物及び治療方法
JP2015504066A (ja) 2012-01-05 2015-02-05 プレッドファルマ・アーベー カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｐｈａｒｍａｃｏｌｏｇｙ， ２０１５年， Ｖｏｌ．８０， Ｎｏ．３， ｐｐ．３５１－３６２

Also Published As

Publication number Publication date
JP2019501226A (ja) 2019-01-17
US20190015424A1 (en) 2019-01-17
AU2017208123B2 (en) 2022-04-21
EP3842040A1 (en) 2021-06-30
WO2017122120A1 (en) 2017-07-20
RU2018128793A (ru) 2020-02-13
RU2018128793A3 (enExample) 2020-05-25
JP2022019973A (ja) 2022-01-27
CA3010915C (en) 2024-06-04
AU2017208123A1 (en) 2018-07-19
US20220133739A1 (en) 2022-05-05
US12303516B2 (en) 2025-05-20
US11260060B2 (en) 2022-03-01
EP3402475A1 (en) 2018-11-21
JP7374163B2 (ja) 2023-11-06
CA3010915A1 (en) 2017-07-20
EP3842040B1 (en) 2022-03-09
CN108601757A (zh) 2018-09-28
EP3402475B1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
JP7374163B2 (ja) 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
Fishbane et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy
Fishbane N-acetylcysteine in the prevention of contrast-induced nephropathy
Macciò et al. Cisplatin: an old drug with a newfound efficacy–from mechanisms of action to cytotoxicity
JP7093669B2 (ja) 即効型インスリン組成物
Anderson et al. Dapagliflozin for the treatment of type 2 diabetes
Hristov The role of glutathione metabolism in chronic illness development and its potential use as a novel therapeutic target
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
Pollock et al. Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy
Jeon et al. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients
Akpınar et al. Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report
Demiroren et al. A comparison of the effects of thymoquinone, silymarin and N-acetylcysteine in an experimental hepatotoxicity
JP2019501226A5 (enExample)
WO2013089164A1 (ja) 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤
Shah et al. The role of catalytic iron in acute kidney injury
Kociancic et al. Acetaminophen intoxication and length of treatment: how long is long enough?
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
Mayoral et al. Drug-induced liver disease
Patel et al. Amlodipine overdose
HK40056482B (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
HK40056482A (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
Jeon et al. Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report
JPH03502805A (ja) 腎保護持続注入液
TWI833222B (zh) 聯合療法
HK1260784B (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220304

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220309

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220401

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220406

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230706

R150 Certificate of patent or registration of utility model

Ref document number: 7311267

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150